Join to view full profile
3100 Plaza Properties BlvdColumbus, OH 43219
Phone+1 614-383-6000
Fax+1 614-383-6001
Dr. Chidiac is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1995 - 1998
Mount Carmel Health SystemResidency, Internal Medicine, 1991 - 1994
St Joseph's University Medical SchoolClass of 1990
Certifications & Licensure
OH State Medical License 1993 - 2027
GA State Medical License 1994 - 1995
PA State Medical License 1994 - 1995
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
Clinical Trials
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Publications & Presentations
PubMed
- 5 citationsPatients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase InhibitorsAlexa B. Schrock, Russell Madison, Margaret Rosenzweig, Justin M. Allen, Rachel L. Erlich
Lung Cancer. 2020-04-17 - 81 citationsPhase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933Sylvia Lee, James C. Moon, Bruce G. Redman, Tarek Chidiac, Lawrence E. Flaherty
Cancer. 2015-02-01 - 59 citationsDisrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.Christina Wu, Soledad Fernandez, Tamara Criswell, Tarek A. Chidiac, Denis C. Guttridge
Pancreas. 2013-07-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
